Eisai presents new Leqembi analyses

31 March 2023

brain_alzheimer_credit_depositphotos_large

Japanese drugmaker Eisai (TYO: 4523) and its partner Biogen (Nasdaq: BIIB) have presented new analyses on Leqembi (lecanemab), the Alzheimer’s drug that gained US approval in January.

The analyses are from the Clarity AD Phase III trial, which met its primary endpoint of slowing cognitive decline, along with all key secondary endpoints, with highly statistically significant results.

These new analyses are on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H (combined cerebral microhemorrhages, superficial siderosis, and intracerebral hemorrhages of more than 1cm in diameter), and caregiver burden and health-related quality of life.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK